AR104145A1 - Método de producción de epirrubicina, intermediario y sal farmacéutica - Google Patents
Método de producción de epirrubicina, intermediario y sal farmacéuticaInfo
- Publication number
- AR104145A1 AR104145A1 ARP160100856A ARP160100856A AR104145A1 AR 104145 A1 AR104145 A1 AR 104145A1 AR P160100856 A ARP160100856 A AR P160100856A AR P160100856 A ARP160100856 A AR P160100856A AR 104145 A1 AR104145 A1 AR 104145A1
- Authority
- AR
- Argentina
- Prior art keywords
- daunorubicin
- epi
- organic acid
- solvates
- hydrates
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title 1
- 150000004677 hydrates Chemical class 0.000 abstract 4
- -1 organic acid salt Chemical class 0.000 abstract 4
- 239000012453 solvate Substances 0.000 abstract 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid group Chemical group C(C(=O)O)(=O)O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 3
- 150000007524 organic acids Chemical class 0.000 abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 abstract 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 abstract 1
- 229940092714 benzenesulfonic acid Drugs 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- 229960001904 epirubicin Drugs 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 235000006408 oxalic acid Nutrition 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
- C07B63/02—Purification; Separation; Stabilisation; Use of additives by treatment giving rise to a chemical modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/385—Saturated compounds containing a keto group being part of a ring
- C07C49/417—Saturated compounds containing a keto group being part of a ring polycyclic
- C07C49/423—Saturated compounds containing a keto group being part of a ring polycyclic a keto group being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
- C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Es posible remover de modo eficaz la 13-dihidroepi-daunorrubicina y la 4-epi-feudomicina, que son típicas impurezas posiblemente contenidas en la 4-epi-daunorrubicina como un material de partida, usando una sal de ácido orgánico de 4-epi-daunorrubicina o uno de sus hidratos o solvatos como un intermediario de producción, haciendo así posible producir epirrubicina de alta pureza. Reivindicación 1: Un método de producción de una sal de ácido orgánico de 4-epi-daunorrubicina o uno de sus hidratos o solvatos, caracterizado porque comprende una etapa de mezcla de 4-epi-daunorrubicina de la fórmula (1) con un ácido orgánico en un solvente para formar una sal de ácido orgánico de 4-epi-daunorrubicina de la fórmula (2) en donde HA representa un ácido orgánico, o uno de sus hidratos o solvatos. Reivindicación 9: Una sal de ácido orgánico de 4-epi-daunorrubicina caracterizada por la fórmula (2) en donde HA representa ácido oxálico, ácido bencensulfónico o ácido p-toluensulfónico, o uno de sus hidratos o solvatos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015067957 | 2015-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104145A1 true AR104145A1 (es) | 2017-06-28 |
Family
ID=57006010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100856A AR104145A1 (es) | 2015-03-30 | 2016-03-30 | Método de producción de epirrubicina, intermediario y sal farmacéutica |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10301343B2 (es) |
| EP (1) | EP3279206B1 (es) |
| JP (1) | JP6682504B2 (es) |
| KR (1) | KR102155411B1 (es) |
| CN (1) | CN107683284B (es) |
| AR (1) | AR104145A1 (es) |
| ES (1) | ES2805723T3 (es) |
| TW (1) | TWI712611B (es) |
| WO (1) | WO2016159092A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109666050B (zh) * | 2017-10-16 | 2023-09-12 | 鲁南制药集团股份有限公司 | 一种盐酸表柔比星晶型ⅲ及其制备方法 |
| CN109836466B (zh) * | 2017-11-24 | 2024-01-19 | 鲁南制药集团股份有限公司 | 一种盐酸表柔比星的晶型及其制备方法 |
| CN114149473B (zh) * | 2020-09-08 | 2024-03-15 | 鲁南制药集团股份有限公司 | 一种盐酸表柔比星的合成方法及其中间体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1506200A (en) | 1975-04-30 | 1978-04-05 | Farmaceutici Italia | Glycosides |
| US4345068A (en) * | 1979-11-22 | 1982-08-17 | Farmitalia Carlo Erba S.P.A. | Process for the preparation of 4'-epidaunorubicin, 3',4'-diepidaunorubicin, their doxorubicin analogs, and intermediates used in said process |
| CN85103908A (zh) * | 1985-07-16 | 1986-11-05 | 法米塔利·卡洛·埃尔巴有限公司 | 制备4′-表多克索红菌素的新方法 |
| IT1230505B (it) * | 1988-10-11 | 1991-10-25 | Sicor Spa | Procedimento per la conversione della daunorubicina in doxorubicina. |
| JP2915252B2 (ja) * | 1993-06-30 | 1999-07-05 | 明治製菓株式会社 | 溶解性が改善された製剤の製造法 |
| DE69609845T2 (de) | 1996-12-16 | 2000-12-21 | Pharmachemie B.V., Haarlem | Verfahren zur Herstellung von Epirubicin oder Zusatzsalzen davon, von Daunorubicin |
| EP2192172B1 (en) | 2003-02-03 | 2014-12-03 | iBio, Inc. | System for expression of genes in plants |
| US7388083B2 (en) * | 2005-03-07 | 2008-06-17 | Solux Corporation | Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics |
| US8802830B2 (en) * | 2005-12-20 | 2014-08-12 | Solux Corporation | Synthesis of epirubicin from 13-dihydrodaunorubicine |
| JP2007261976A (ja) | 2006-03-28 | 2007-10-11 | Meiji Seika Kaisha Ltd | 抗腫瘍性アンスラサイクリン系抗生物質の製造法 |
| JP2007267976A (ja) * | 2006-03-31 | 2007-10-18 | Dragon:Kk | 麻雀ゲーム機 |
| DK1990405T3 (da) * | 2007-05-08 | 2017-11-06 | Provivo Oy | Genetisk modificerede stammer, der producerer anthracyclin-metabolitter anvendelige som kræftmedicin |
| US8383392B2 (en) * | 2007-09-14 | 2013-02-26 | Meiji Seika Pharma Co., Ltd. | Transformant and method for production of non-natural antibiotic |
| EP2301943B1 (en) | 2009-09-08 | 2014-01-08 | Heraeus Precious Metals GmbH & Co. KG | Crystallization of epidaunorubicin x HCI |
| WO2011145211A1 (ja) * | 2010-05-21 | 2011-11-24 | 明治製菓株式会社 | ケトレダクターゼ変異体 |
| EP2778171A1 (en) * | 2013-03-15 | 2014-09-17 | Synbias Pharma Ltd. | Crystalline monohydrate of epirubicin hydrochloride |
-
2016
- 2016-03-30 KR KR1020177027969A patent/KR102155411B1/ko active Active
- 2016-03-30 CN CN201680019370.7A patent/CN107683284B/zh active Active
- 2016-03-30 EP EP16772973.0A patent/EP3279206B1/en active Active
- 2016-03-30 JP JP2017510110A patent/JP6682504B2/ja active Active
- 2016-03-30 AR ARP160100856A patent/AR104145A1/es unknown
- 2016-03-30 WO PCT/JP2016/060409 patent/WO2016159092A1/ja not_active Ceased
- 2016-03-30 TW TW105110084A patent/TWI712611B/zh active
- 2016-03-30 US US15/562,482 patent/US10301343B2/en active Active
- 2016-03-30 ES ES16772973T patent/ES2805723T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180009737A (ko) | 2018-01-29 |
| ES2805723T3 (es) | 2021-02-15 |
| TW201706282A (zh) | 2017-02-16 |
| CN107683284A (zh) | 2018-02-09 |
| CN107683284B (zh) | 2021-05-11 |
| US10301343B2 (en) | 2019-05-28 |
| KR102155411B1 (ko) | 2020-09-11 |
| TWI712611B (zh) | 2020-12-11 |
| WO2016159092A1 (ja) | 2016-10-06 |
| EP3279206A1 (en) | 2018-02-07 |
| JP6682504B2 (ja) | 2020-04-15 |
| US20180094014A1 (en) | 2018-04-05 |
| EP3279206A4 (en) | 2018-12-26 |
| EP3279206B1 (en) | 2020-04-22 |
| JPWO2016159092A1 (ja) | 2018-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR133546A2 (es) | Proceso para preparar pridopidina | |
| CY1121395T1 (el) | Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6 | |
| CL2018003323A1 (es) | Piridinas sustituidas con heteroarilo y métodos de uso. | |
| CO2017002253A2 (es) | Compuesto dirigido a il-23a y tnf-alfa | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| EP3359666C0 (en) | EARLY POST-TRANSFECTION ISOLATION OF CELLS TO PREPARE BIOLOGICAL PRODUCTS | |
| EA201401292A2 (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| EP3412274A4 (en) | AQUEOUS SOLUTION WITH UROLITHINES, DRY SOLID COMPOSITION, AND PRODUCTION PROCESS THEREFOR, AND PROCESSES FOR STABILIZING UROLITHINES | |
| BR112016017570A2 (pt) | Borracha estabilizada, processo para preparar as borrachas estabilizadas, mistura vulcanizável, processo para a preparação da mistura vulcanizável, processo para preparar vulcanizados da mistura vulcanizável, e, vulcanizado | |
| AR101434A1 (es) | Método para producir (r)-1,1,3-trimetil-4-aminoindano | |
| EP3626701A4 (en) | FLUORINATED CARBONATE DERIVATIVE MANUFACTURING PROCESS | |
| MX388969B (es) | Formulas cristalinas de grapiprant. | |
| BR112018073490A2 (pt) | 6.7.beta-epóxidos esteroides como intermediários químicos | |
| CY1115933T1 (el) | Διϋποκατεστημενες ενωσεις τετραϋδροφουρανυλιου ως ανταγωνιστες toy β1-υποδοχεα βραδυκινινης | |
| BR112016025024A2 (pt) | ?processo para preparar compostos ceto, e, uso de farnesil acetona? | |
| AR104145A1 (es) | Método de producción de epirrubicina, intermediario y sal farmacéutica | |
| EP3891114A4 (en) | METHODS FOR THE PRODUCTION OF HIGH PURITY TRIFLUOROIODOMETHANE | |
| AR098053A1 (es) | Proceso para la síntesis industrial de lurasidona | |
| AR099070A1 (es) | Ácido (s)- 3-metil-abscísico y ésteres del mismo | |
| BR112016024977A2 (pt) | processo para a preparação de polimorfos de imidacloprida | |
| BR112017006967A2 (pt) | produção aperfeiçoada de 5-hidroximetilfurfural, sob uso de um composto de álcool multifluorado | |
| EA201891237A1 (ru) | Удаление гипса из выщелачивающего раствора | |
| EP3554675A4 (en) | PURIFICATION PROCESS FOR THE PRODUCTION OF ULTRA PUR CARBON MONOXIDE | |
| EP3559121A4 (en) | NEW PROCESS FOR THE PREPARATION OF SODIUM INDIGOTINDISULPHONATE (INDIGO CARMIN) | |
| BR112018076814A2 (pt) | produção de anidrido de sulfonil azida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |